JP2020509737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509737A5 JP2020509737A5 JP2019542396A JP2019542396A JP2020509737A5 JP 2020509737 A5 JP2020509737 A5 JP 2020509737A5 JP 2019542396 A JP2019542396 A JP 2019542396A JP 2019542396 A JP2019542396 A JP 2019542396A JP 2020509737 A5 JP2020509737 A5 JP 2020509737A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- cancer
- antibody
- specifically binds
- bifunctional fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710151979.6 | 2017-03-15 | ||
| CN201710151979.6A CN108623689B (zh) | 2017-03-15 | 2017-03-15 | 新型重组双功能融合蛋白及其制备方法和用途 |
| PCT/CN2018/079187 WO2018166507A1 (zh) | 2017-03-15 | 2018-03-15 | 新型重组双功能融合蛋白及其制备方法和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509737A JP2020509737A (ja) | 2020-04-02 |
| JP2020509737A5 true JP2020509737A5 (enExample) | 2021-12-23 |
| JP7056858B2 JP7056858B2 (ja) | 2022-04-19 |
Family
ID=63522802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542396A Active JP7056858B2 (ja) | 2017-03-15 | 2018-03-15 | 新規な組換え型二機能性融合タンパク質、その調製方法および用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11407841B2 (enExample) |
| EP (1) | EP3626747B1 (enExample) |
| JP (1) | JP7056858B2 (enExample) |
| CN (2) | CN108623689B (enExample) |
| ES (1) | ES2960311T3 (enExample) |
| WO (1) | WO2018166507A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112533954B (zh) * | 2018-08-08 | 2024-06-18 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向cd47和her2的重组双功能蛋白 |
| BR112021008486A2 (pt) * | 2018-11-01 | 2021-10-26 | Shandong New Time Pharmaceutical Co., Ltd | Anticorpo biespecífico e seu uso |
| KR20210107062A (ko) * | 2018-12-21 | 2021-08-31 | 오제 이뮈노테라프틱스 | 이작용성 항-PD-1/SIRPα 분자 |
| CN111484558B (zh) * | 2019-01-28 | 2023-02-17 | 上海交通大学 | 信号调节蛋白α片段-抗FcRn单链抗体融合蛋白及其制备与应用 |
| CN111423515A (zh) * | 2020-03-23 | 2020-07-17 | 倍而达药业（苏州）有限公司 | 一种cd20/cd47双特异性抗体及应用 |
| CN113896802A (zh) * | 2021-10-09 | 2022-01-07 | 宜明昂科生物医药技术（上海）有限公司 | 靶向cd47和cd38的重组融合蛋白及其制备和用途 |
| CN113956363B (zh) | 2021-10-13 | 2023-03-31 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向cd47和cd24的重组融合蛋白及其制备和用途 |
| WO2023072217A1 (en) * | 2021-10-28 | 2023-05-04 | Guangzhou Lintonpharm Co., Ltd. | Fusion proteins targeting cd3 and cd47 |
| WO2024179545A1 (zh) * | 2023-03-01 | 2024-09-06 | 上海津曼特生物科技有限公司 | 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014227638A1 (en) * | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| WO2016022971A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
| AU2015303135B2 (en) * | 2014-08-15 | 2021-05-20 | Merck Patent Gmbh | SIRP-alpha immunoglobulin fusion proteins |
| CN114425077A (zh) * | 2015-05-18 | 2022-05-03 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
-
2017
- 2017-03-15 CN CN201710151979.6A patent/CN108623689B/zh active Active
-
2018
- 2018-03-15 CN CN201880011334.5A patent/CN110300766B/zh active Active
- 2018-03-15 EP EP18768501.1A patent/EP3626747B1/en active Active
- 2018-03-15 US US16/489,360 patent/US11407841B2/en active Active
- 2018-03-15 JP JP2019542396A patent/JP7056858B2/ja active Active
- 2018-03-15 WO PCT/CN2018/079187 patent/WO2018166507A1/zh not_active Ceased
- 2018-03-15 ES ES18768501T patent/ES2960311T3/es active Active
-
2021
- 2021-08-23 US US17/408,768 patent/US20220010031A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509737A5 (enExample) | ||
| CN110835371A (zh) | 抗ccr8单克隆抗体及其应用 | |
| JP6472784B2 (ja) | 細胞内在化を誘導するためのｃｄ２０結合免疫毒素及びそれを用いる方法 | |
| AU2020316002A1 (en) | Compositions and methods comprising protease-activated therapeutic agents | |
| JP2017529059A5 (enExample) | ||
| CN110835374A (zh) | 抗ccr8×ctla-4双特异性抗体及其应用 | |
| US20170260246A1 (en) | Carcinoma homing peptide (chp), its analogs, and methods of using | |
| Altai et al. | Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: development of an optimized conjugation protocol and 177Lu labeling | |
| JP2024517871A (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| CN116832177A (zh) | 干扰趋化素样因子超家族成员6(cmtm6)表达的基因治疗载体的制备和抗肿瘤应用 | |
| WO2023072405A1 (en) | Ykl-40 antibody and uses thereof | |
| WO2017211278A1 (en) | Antibody fusion proteins for drug delivery | |
| JP7179855B2 (ja) | 低ｐＨ挿入ペプチド及びその組成物 | |
| WO2025045097A1 (zh) | 靶向hbv全长包膜蛋白的单域抗体及其用途 | |
| CN101210048A (zh) | 用于靶向结合髓系白血病细胞的抗cd33的工程抗体及其表达载体和用途 | |
| CN115724988B (zh) | 一种接近天然分子的多肽融合分子 | |
| CN109400711B (zh) | 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 | |
| CN117924516A (zh) | 一种提高adc药物疗效的重组蛋白及其应用 | |
| CN102260352B (zh) | 靶向性白细胞介素融合蛋白及其制备方法与应用 | |
| US10428132B2 (en) | Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof | |
| CN104119444B (zh) | 抗肿瘤融合蛋白及其制备方法和用途 | |
| CN112661845B (zh) | 与cxcr4结合的亲和力成熟结合蛋白及其应用 | |
| CN117925726A (zh) | 基于多价多肽识别的car-nk细胞的构建方法及应用 | |
| WO2023066389A1 (zh) | 靶向pd-1的双特异性抗体、及其制备和应用 | |
| HK40106237A (en) | Polypeptide fusion molecule close to natural molecule |